The Issue:
Children with cancer face limited treatment options compared to adults, as most drugs are initially developed for adult patients. Differences in biology, safety profiles, and dosing make pediatric drug development complex and often delayed.
The Approach:
Innovative clinical strategies, including age appropriate trials, adaptive study designs, and collaborations between industry and regulatory agencies, are helping accelerate pediatric oncology research. Advanced preclinical models and biomarker driven approaches improve the selection of safe and effective therapies for children.
The Benefits:
Faster development of pediatric cancer therapies ensures children have access to treatments that are safer, more effective, and tailored to their needs. Closing this gap improves survival outcomes, reduces long-term side effects, and strengthens overall pediatric cancer care.
